- Region
- Vega baja
- Marina Alta
- Marina Baixa
- Alicante
- Baix Vinalopo
- Alto & Mitja Vinalopo
-
ALL TOWNS
- ALICANTE TOWNS
- Albatera
- Alfaz Del Pi
- Alicante City
- Alcoy
- Almoradi
- Benitatxell
- Bigastro
- Benferri
- Benidorm
- Calosa de Segura
- Calpe
- Catral
- Costa Blanca
- Cox
- Daya Vieja
- Denia
- Elche
- Elda
- Granja de Rocamora
- Guardamar del Segura
- Jacarilla
- Los Montesinos
- Orihuela
- Pedreguer
- Pilar de Horadada
- Playa Flamenca
- Quesada
- Rafal
- Redovan
- Rojales
- San Isidro
- Torrevieja
- Comunidad Valenciana
- EDITIONS: Spanish News Today Murcia Today Andalucia Today
Date Published: 20/12/2021
ARCHIVED - EU backs US Novavax vaccine
European Medicines Agency gives the all-clear to use previously unapproved Novavax vaccine
The European Medicines Agency (EMA) endorsed the use of the US vaccine Novavax as “safe and effective” on Monday December 20, and recommended that it be licensed, making it the fifth Covid vaccine to pass Europe’s scientific filter.
The vaccine is recommended for adults 18 years and older, should be administered in two doses, 21 days apart. This means that anyone who gets their first dose of Novavax should be given their second jab three weeks later, according to recommendations, though in reality governments’ policies on this can change depending on their vaccine stocks and vaccination strategy.
Officially licensed as the NVX-CoV2373 vaccine by the Maryland-based company Novavax, the vaccine has been less popular than other vaccines like Pfizer, Moderna, Janssen and, formerly, AstraZeneca.
One of the setbacks that left Novavax out in the cold in comparison with its competitors was not being certified by the US Food and Drug Administration (FDA), the World Health Organisation (WHO) and other global health bodies. Part of the reason for this was a supposed problem with purity levels – the FDA requests that each batch of a coronavirus vaccine have at least 90% purity, but several samples of Novavax showed levels around 70%.
Now having been approved by the EMA, it’s thought Novavax will have a global resurgence and be able to fulfil its commitment, signed earlier this year, to provide 100 million doses to the EU, with an option for an additional 100 million if all goes well.
Novavax has already stated that their vaccine is effective against new variants of the virus, such as Omicron, but can be adapted if needs be to specifically target different strains.
Image: Archive
staff.inc.ali
Loading
Read more about Coronavirus:
OR
Sign up for the Spanish News Today Editors Roundup Weekly Bulletin to get a comprehensive email with all the week’s news for Spain, Murcia, Alicante and Andalucía.
Get a sneak peek – here are a few of our recent Subscription Bulletins:
50% Discount Special Offer subscription:
24.95€ for 48 Editor’s Weekly News Roundup bulletins!
Please CLICK THE BUTTON to subscribe.
Contact Murcia Today: Editorial 000 000 000 /
Office 000 000 000